Sana Biotechnology, Inc. $SANA Shares Sold by Baker BROS. Advisors LP

Key Points

• Baker BROS. Advisors LP reduced its stake in Sana Biotechnology by 14.7%, selling 350,000 shares, leaving it with approximately 2 million shares valued at about $3.4 million.
• Analysts have set a target price for Sana Biotechnology shares, with JMP Securities maintaining a market outperform rating and a price objective of $5.00, while Morgan Stanley rated it as overweight with a target of $12.00.
• Sana Biotechnology's shares currently trade at $3.06, with a 12-month low of $1.26 and high of $7.30, and the company reported a loss of ($0.16) earnings per share in its most recent quarter.

Baker BROS. Advisors LP decreased its holdings in shares of Sana Biotechnology, Inc. (NASDAQ:SANA - Free Report) by 14.7% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,030,949 shares of the company's stock after selling 350,000 shares during the quarter. Baker BROS. Advisors LP owned about 0.90% of Sana Biotechnology worth $3,412,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Tower Research Capital LLC TRC lifted its holdings in shares of Sana Biotechnology by 229.9% during the 4th quarter. Tower Research Capital LLC TRC now owns 15,136 shares of the company's stock valued at $25,000 after acquiring an additional 10,548 shares in the last quarter. Pallas Capital Advisors LLC acquired a new position in shares of Sana Biotechnology during the 1st quarter valued at $29,000. Ameriprise Financial Inc. acquired a new position in shares of Sana Biotechnology during the 4th quarter valued at $29,000. BNP Paribas Financial Markets acquired a new position in shares of Sana Biotechnology during the 4th quarter valued at $34,000. Finally, Focus Partners Wealth acquired a new position in shares of Sana Biotechnology during the 4th quarter valued at $35,000. Institutional investors and hedge funds own 88.23% of the company's stock.

Analysts Set New Price Targets

A number of equities analysts have commented on SANA shares. JMP Securities reiterated a "market outperform" rating and issued a $5.00 price objective on shares of Sana Biotechnology in a report on Tuesday, June 24th. Morgan Stanley started coverage on shares of Sana Biotechnology in a report on Thursday, July 3rd. They issued an "overweight" rating and a $12.00 price objective on the stock. Six equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company presently has an average rating of "Buy" and an average target price of $8.00.

Sana Biotechnology Price Performance

Shares of SANA stock opened at $3.06 on Tuesday. Sana Biotechnology, Inc. has a 12 month low of $1.26 and a 12 month high of $7.30. The firm has a market capitalization of $727.70 million, a P/E ratio of -2.89 and a beta of 1.88. The company's fifty day moving average price is $3.70 and its two-hundred day moving average price is $2.70.

Sana Biotechnology (NASDAQ:SANA - Get Free Report) last released its earnings results on Monday, August 11th. The company reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.20) by $0.04. On average, sell-side analysts anticipate that Sana Biotechnology, Inc. will post -1.16 EPS for the current year.

About Sana Biotechnology

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.

Want to see what other hedge funds are holding SANA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sana Biotechnology, Inc. (NASDAQ:SANA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.